Rapalogix Health raises Series A co-led by Woodline Partners and GordonMD Global Investments

What's the deal? Rapalogix Health has raised a Series A funding round, co-led by Woodline PartnersDealroom has a profile for this one. Try Dealroom → and GordonMD Global InvestmentsDealroom has a profile for this one. Try Dealroom →.

The financing was announced in June 2026.

Why now? The raise lands as investors continue to pour capital into health-focused startups, betting on companies that pair medicine with new technology.

The signal: Rapalogix is an early-stage company built around skin longevity solutions that target cellular aging pathways, placing it at the intersection of dermatology and the fast-growing longevity field. Securing two investment funds to co-lead its Series A suggests backers see room for the company to scale a specialised approach within that emerging market.

Read more: AInvest

Image credit: AI-generated image (Gemini)